A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 7vPnC in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 11 sites in United Kingdom. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-24.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccines in the United Kingdom.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
13-valent pneumococcal vaccine
Biological: 13-valent Pneumococcal Conjugate Vaccine · Biological: Pediacel · Biological: NeisVac-C · Biological: Menitorix
7-valent pneumococcal vaccine
Biological: 7vPnC · Biological: Pediacel · Biological: NeisVac-C · Biological: Menitorix
Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series.
Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥1:8 and predefined antibody threshold levels with the corresponding 95% CI for concomitant antigens polyribosylribitol phosphate (PRP) in haemophilus influenzae type b \[Hib\](≥0.15 μg/mL or ≥ 1.0 μg/mL), pertussis toxoid \[PT\], filamentous haemagglutinin, pertactin \[FHA\], and pertactin (PRN) (≥5 Elisa Units EU/mL) and fimbrial agglutinogens \[FIM\] (≥2.2 EU/mL) are presented.
Time frame: One month after infant series dose 2 (5 months of age)
Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series
Time frame: one month after infant series dose 2 (5 months of age)
Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series
Time frame: one month after infant series dose 2 (5 months of age)
Geometric Mean Antibody Concentration of Pertusis Filamentous Haemagglutinin (FHA), Pertussis Toxoid (PT), Pertactin (PRN), and Fimbrial Agglutinogens (FIM) as Measured by ELISA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series
Time frame: one month after infant series dose 2 (5 months of age)
Percentage of Participants in the 13vPnC Group Achieving a Serotype-specific IgG Antibody Concentration ≥0.35 µg/mL Measured 1 Month After the 2-dose Infant Series, Before and After the Toddler Dose
Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: one month after infant series dose 2 (5 months of age), before and after toddler dose (12 months of age)
Geometric Mean Antibody Concentration in 13vPnC Group After the 2-dose Infant Series, Before and After the Toddler Dose.
Antibody concentration/geometric mean concentration (GMC) as measured by ELISA for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented with corresponding 2-sided 95% CI.
Time frame: one month after infant series dose 2 (5 months of age) and before and after toddler dose (12 months of age)
Percentage of Participants Achieving an SBA Titer ≥1:8 for Meningococcal C in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose.
Time frame: one month after the toddler dose (13 months of age)
Percentage of Participants Achieving a Predefined Antibody Level for Haemophilus Influenzae Type b in the 13vPnC Group Relative to the 7vPnC Group After the Toddler Dose.
Time frame: one month after toddler dose (13 months of age)
Geometric Mean Antibody Concentration for Haemophilus Influenzae Type b PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose.
Time frame: one month after toddler dose (13 months of age)
Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Time frame: one month after toddler dose (13 months of age)
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events
Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds) to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary; percentage of participants with each event was evaluated.
Time frame: During the 4-day period after each dose
Participants were recruited in the United Kingdom (UK) from October 2006 to June 2007.
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 141 | 145 |
| Vaccinated dose 1 | 139 | 139 |
| Vaccinated dose 2 | 136 | 135 |
| Completed | 135 | 132 |
| Not completed | 6 | 13 |
| Withdrew: Not consented | 2 | 6 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 135 | 132 |
| Completed | 131 | 122 |
| Not completed | 4 | 10 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Failed to return | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 131 | 122 |
| Completed | 130 | 120 |
| Not completed | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Failed to return | 0 | 1 |
Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥1:8 and predefined antibody threshold levels with the corresponding 95% CI for concomitant antigens polyribosylribitol phosphate (PRP) in haemophilus influenzae type b \[Hib\](≥0.15 μg/mL or ≥ 1.0 μg/mL), pertussis toxoid \[PT\], filamentous haemagglutinin, pertactin \[FHA\], and pertactin (PRN) (≥5 Elisa Units EU/mL) and fimbrial agglutinogens \[FIM\] (≥2.2 EU/mL) are presented.
| Percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Meningococcal C ≥ 1:8 titer (n=120,118) | 99.2 (95.4 to 100.0) | 99.2 (95.4 to 100.0) |
| Hib (PRP) ≥ 0.15 μg/mL (n=114,102) | 96.5 (91.3 to 99.0) | 98.0 (93.1 to 99.8) |
| Hib (PRP) ≥ 1.0 μg/mL (n=114,102) | 85.1 (77.2 to 91.1) | 89.2 (81.5 to 94.5) |
| Pertussis PT ≥ 5 EU/mL (n=119,112) | 100.0 (96.9 to 100.0) | 100.0 (96.8 to 100.0) |
| Pertussis PT ≥ 17 EU/mL (n=119,112) | 96.6 (91.6 to 99.1) | 95.5 (89.9 to 98.5) |
| Pertussis FHA ≥ 5 EU/mL (n=119,113) | 100.0 (96.9 to 100.0) | 100.0 (96.8 to 100.0) |
| Pertussis FHA ≥ 7.82 EU/mL (n=119,113) | 100.0 (96.9 to 100.0) | 100.0 (96.8 to 100.0) |
| Pertussis FHA ≥ 20 EU/mL (n=119,113) | 94.1 (88.3 to 97.6) | 95.6 (90.0 to 98.5) |
| Pertussis PRN ≥ 5 EU/mL (n=119,113) | 100.0 (96.9 to 100.0) | 100.0 (96.8 to 100.0) |
| Pertussis PRN ≥ 15 EU/mL (n=119,113) | 92.4 (86.1 to 96.5) | 95.6 (90.0 to 98.5) |
| Pertussis FIM ≥ 2.2 EU/mL (n=119,113) | 100.0 (96.9 to 100.0) | 97.3 (92.4 to 99.4) |
| Pertussis FIM ≥ 5 EU/mL (n=119,113) | 97.5 (92.8 to 99.5) | 96.5 (91.2 to 99.0) |
| Percentage of Participants | 13vPnC Before Toddler Dose | 7vPnC Before Toddler Dose | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Percentage of Participants Achieving an SBA Titer ≥1:8 for Meningococcal C in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose. | 44.1 (34.3 to 54.3) | 49.5 (38.9 to 60.0) | 91.7 (84.9 to 96.2) | 91.8 (84.5 to 96.4) |
| Percentage of Participants | 13vPnC | 7vPnC |
|---|---|---|
| Hib (PRP) ≥0.15 μg/mL | 100.0 (96.5 to 100.0) | 100.0 (96.2 to 100.0) |
| Hib (PRP)≥1.0 μg/mL | 99.0 (94.8 to 100.0) | 100.0 (96.2 to 100.0) |
| titer | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series | 306.20 (251.21 to 373.22) | 345.42 (287.91 to 414.41) |
| μg/mL | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series | 3.40 (2.65 to 4.37) | 4.44 (3.50 to 5.63) |
| EU/mL | 13vPnC | 7vPnC |
|---|---|---|
| Pertussis FHA (n=119,113) | 54.74 (48.25 to 373.22) | 55.99 (49.55 to 414.41) |
| Pertussis PT (n=119,112) | 66.26 (59.20 to 74.16) | 67.05 (58.75 to 76.52) |
| Pertussis PRN (n=119,113) | 61.33 (51.78 to 72.65) | 61.07 (52.31 to 71.30) |
| Pertussis FIM (n=119,113) | 21.72 (18.89 to 24.98) | 21.77 (18.54 to 25.56) |
| μg/mL | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Antibody Concentration for Haemophilus Influenzae Type b PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose. | 22.22 (17.66 to 27.96) | 19.75 (16.05 to 24.30) |
Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| Percentage of Participants | 13vPnC After Infant Series Dose 2 | 13vPnC Before Toddler Dose | 13vPnC After Toddler Dose |
|---|---|---|---|
| Common Serotypes - Serotype 4 (n=107,89,102) | 95.3 (89.4 to 98.5) | 24.7 (16.2 to 35.0) | 99.0 (94.7 to 100.0) |
| Common Serotypes - Serotype 6B (n=107,86,102) | 40.2 (30.8 to 50.1) | 74.4 (63.9 to 83.2) | 98.0 (93.1 to 99.8) |
| Common Serotypes - Serotype 9V (n=104,91,101) | 85.6 (77.3 to 91.7) | 44.0 (33.6 to 54.8) | 98.0 (93.0 to 99.8) |
| Common Serotypes - Serotype 14 (n=107,88,101) | 92.5 (85.8 to 96.7) | 92.0 (84.3 to 96.7) | 100.0 (96.4 to 100.0) |
| Common Serotypes - Serotype 18C (n=111,91,105) | 92.8 (86.3 to 96.8) | 13.2 (7.0 to 21.9) | 97.1 (91.9 to 99.4) |
| Common Serotypes - Serotype 19F (n=109,91,104) | 93.6 (87.2 to 97.4) | 67.0 (56.4 to 76.5) | 98.1 (93.2 to 99.8) |
| Common Serotypes - Serotype 23F (n=111,89,104) | 66.7 (57.1 to 75.3) | 37.1 (27.1 to 48.0) | 98.1 (93.2 to 99.8) |
| Additional Serotypes - Serotype 1 (n=107,88,101) | 97.2 (92.0 to 99.4) | 50.0 (39.1 to 60.9) | 100.0 (96.4 to 100.0) |
| Additional Serotypes - Serotype 3 (n=107,87,102) | 86.0 (77.9 to 91.9) | 12.6 (6.5 to 21.5) | 88.2 (80.4 to 93.8) |
| Additional Serotypes - Serotype 5 (n=103,88,101) | 89.3 (81.7 to 94.5) | 78.4 (68.4 to 86.5) | 100.0 (96.4 to 100.0) |
| Additional Serotypes - Serotype 6A (n=106,86,99) | 79.2 (70.3 to 86.5) | 79.1 (69.0 to 87.1) | 98.0 (92.9 to 99.8) |
| Additional Serotypes - Serotype 7F (n=107,91,100) | 94.4 (88.2 to 97.9) | 71.4 (61.0 to 80.4) | 100.0 (96.4 to 100.0) |
| Additional Serotypes - Serotype 19A (n=110,91,103) | 92.7 (86.2 to 96.8) | 86.8 (78.1 to 93.0) | 100.0 (96.5 to 100.0) |
Antibody concentration/geometric mean concentration (GMC) as measured by ELISA for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented with corresponding 2-sided 95% CI.
| μg/mL | 13vPnC After Infant Series Dose 2 | 13vPnC Before Toddler Dose | 13vPnC After Toddler Dose |
|---|---|---|---|
| Common Serotypes - Serotype 4 (n=107,87,87) | 1.37 (1.16 to 1.62) | 0.21 (0.17 to 0.24) | 3.52 (2.91 to 4.26) |
| Common Serotypes - Serotype 6B (n=107,85,85) | 0.26 (0.21 to 0.33) | 0.77 (0.60 to 0.99) | 7.67 (5.88 to 10.01) |
| Common Serotypes - Serotype 9V (n=104,88,88) | 0.87 (0.72 to 1.05) | 0.29 (0.24 to 0.36) | 2.46 (2.03 to 2.99) |
| Common Serotypes - Serotype 14 (n=107,87,87) | 1.83 (1.47 to 2.27) | 1.34 (1.09 to 1.66) | 11.32 (9.27 to 13.83) |
| Common Serotypes - Serotype 18C (n=111,91,91) | 1.37 (1.14 to 1.64) | 0.20 (0.17 to 0.23) | 2.14 (1.82 to 2.53) |
| Common Serotypes - Serotype 19F (n=109,90,90) | 2.38 (1.88 to 3.01) | 0.60 (0.46 to 0.79) | 7.25 (5.65 to 9.31) |
| Common Serotypes - Serotype 23F (n=111,88,88) | 0.53 (0.42 to 0.67) | 0.24 (0.19 to 0.32) | 3.13 (2.59 to 3.78) |
| Additional Serotypes - Serotype 1 (n=107,85,85) | 1.69 (1.41 to 2.04) | 0.39 (0.33 to 0.46) | 5.60 (4.60 to 6.82) |
| Additional Serotypes - Serotype 3 (n=107,85,85) | 0.63 (0.56 to 0.71) | 0.14 (0.10 to 0.18) | 0.98 (0.78 to 1.22) |
| Additional Serotypes - Serotype 5 (n=103,86,86) | 0.95 (0.79 to 1.14) | 0.59 (0.49 to 0.72) | 3.68 (3.04 to 4.45) |
| Additional Serotypes - Serotype 6A (n=106,83,83) | 0.86 (0.68 to 1.07) | 0.81 (0.64 to 1.03) | 6.31 (5.06 to 7.87) |
| Additional Serotypes - Serotype 7F (n=107,87,87) | 2.14 (1.75 to 2.62) | 0.56 (0.48 to 0.66) | 4.06 (3.42 to 4.83) |
| Additional Serotypes - Serotype 19A (n=110,89,89) | 1.90 (1.54 to 2.34) | 1.01 (0.77 to 1.32) | 11.33 (9.29 to 13.83) |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| Percentage of Participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|
| Tenderness-Any (n=123,127,114,96,87,71) | 44.7 | 43.3 | 42.1 | 40.6 | 44.8 | 50.7 |
| Tenderness-Significant (n=116,122,97,89,77,58) | 1.7 | 6.6 | 4.1 | 4.5 | 3.9 | 3.4 |
| Swelling-Any (n=121,126,106,93,83,68) | 24.8 | 29.4 | 30.2 | 34.4 | 30.1 | 39.7 |
| Swelling-Mild (n=120,125,105,93,82,66) | 21.7 | 27.2 | 28.6 | 29.0 | 28.0 | 34.8 |
| Swelling-Moderate (n=118,121,98,88,77,60) | 6.8 | 6.6 | 8.2 | 6.8 | 3.9 | 11.7 |
| Swelling-Severe (n=115,119,96,88,76,57) | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 0.0 |
| Redness-Any (n=122,126,107,99,85,73) | 22.1 | 39.7 | 39.3 | 40.4 | 38.8 | 53.4 |
| Redness-Mild (n=122,126,106,99,83,71) | 21.3 | 39.7 | 37.7 | 37.4 | 33.7 | 49.3 |
| Redness-Moderate (n=116,119,98,88,78,61) | 1.7 | 0.0 | 4.1 | 3.4 | 12.8 | 16.4 |
| Redness-Severe (n=115,119,97,88,76,57) | 0.0 | 0.0 | 2.1 | 0.0 | 0.0 | 0.0 |
Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds) to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary; percentage of participants with each event was evaluated.
| Percentage of Participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|
| Fever ≥38°C but ≤39°C (n=116,119,96,88,78,61) | 6.0 | 3.4 | 3.1 | 4.5 | 7.7 | 16.4 |
| Fever >39°C but ≤40°C (n=115,119,95,88,76,58) | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 5.2 |
| Fever >40°C (n=115,119,96,88,76,57) | 0.0 | 0.0 | 2.1 | 0.0 | 0.0 | 0.0 |
| Decreased appetite (n=120,129,104,98,92,68) | 39.2 | 34.1 | 35.6 | 37.8 | 39.1 | 44.1 |
| Irritability (n=128,135,117,119,97,80) | 76.6 | 74.1 | 71.8 | 80.7 | 74.2 | 76.3 |
| Increased sleep (n=129,129,114,109,88,71) | 69.8 | 66.7 | 51.8 | 56.9 | 38.6 | 40.8 |
| Decreased sleep (n=119,124,98,100,81,67) | 32.8 | 33.9 | 35.7 | 38.0 | 32.1 | 44.8 |
| Meds to treat symptoms (n=123,128,108,110,85,72) | 43.9 | 40.6 | 50.9 | 54.5 | 49.4 | 58.3 |
| Meds to prevent symptoms (n=122,124,117,103,92,77) | 49.2 | 40.3 | 48.7 | 50.5 | 52.2 | 67.5 |
| titer | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose | 656.11 (445.46 to 966.38) | 771.67 (509.98 to 1167.64) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Infant Series | — | 1/139 (0.7%) | 111/138 (80.4%) |
| 7vPnC Infant Series | — | 3/139 (2.2%) | 105/139 (75.5%) |
| 13vPnC Post-Infant Series | — | 5/139 (3.6%) | 9/138 (6.5%) |
| 7vPnC Post-Infant Series | — | 2/139 (1.4%) | 8/139 (5.8%) |
| 13vPnC Toddler Series | — | 1/131 (0.8%) | 72/130 (55.4%) |
| 7vPnC Toddler Series | — | 2/122 (1.6%) | 61/122 (50%) |
| 13vPnC 6-Month Follow-up | — | 2/138 (1.4%) | 1/138 (0.7%) |
| 7vPnC 6-Month Follow-up | — | 0/139 (0%) | 1/139 (0.7%) |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 0/139 | 0/139 | 0/139 | 0/139 | 0/131 | 1/122 | 0/138 | 0/139 |
| PneumoniaInfections and infestations | 0/139 | 0/139 | 0/139 | 0/139 | 0/131 | 1/122 | 0/138 | 0/139 |
| BronchiolitisInfections and infestations | 1/139 | 0/139 | 1/139 | 0/139 | 1/131 | 0/122 | 0/138 | 0/139 |
| Febrile convulsionNervous system disorders | 0/139 | 0/139 | 0/139 | 0/139 | 0/131 | 0/122 | 1/138 | 0/139 |
| VomitingGastrointestinal disorders | 0/139 | 0/139 | 0/139 | 0/139 | 0/131 | 0/122 | 1/138 | 0/139 |
| Breath holdingPsychiatric disorders | 0/139 | 1/139 | 0/139 | 0/139 | 0/131 | 0/122 | 0/138 | 0/139 |
| CellulitisInfections and infestations | 0/139 | 1/139 | 0/139 | 0/139 | 0/131 | 0/122 | 0/138 | 0/139 |
| GastroenteritisInfections and infestations | 0/139 | 0/139 | 1/139 | 0/139 | 0/131 | 0/122 | 0/138 | 0/139 |
| Gastrooesophaegeal refluxGastrointestinal disorders | 0/139 | 1/139 | 0/139 | 0/139 | 0/131 | 0/122 | 0/138 | 0/139 |
| Head injuryInjury, poisoning and procedural complications | 0/139 | 0/139 | 1/139 | 0/139 | 0/131 | 0/122 | 0/138 | 0/139 |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| IrritabilityGeneral disorders | 84/117 | 96/119 | — | — | — | — | — | — |
| IrritabilityGeneral disorders | 98/128 | 100/135 | — | — | 72/97 | 61/80 | — | — |
| Increased sleepGeneral disorders | 90/129 | 86/129 | — | — | 34/88 | 29/71 | — | — |
| Increased sleepGeneral disorders | 59/114 | 62/109 | — | — | — | — | — | — |
| Erythema (Any)Skin and subcutaneous tissue disorders | 27/122 | 50/126 | — | — | 33/85 | 39/73 | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 55/123 | 55/127 | — | — | 39/87 | 36/71 | — | — |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 26/122 | 50/126 | — | — | 28/83 | 35/71 | — | — |
| Decreased sleepGeneral disorders | 39/119 | 42/124 | — | — | 26/81 | 30/67 | — | — |
| Decreased appetiteGeneral disorders | 47/120 | 44/129 | — | — | 36/92 | 30/68 | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 48/114 | 39/96 | — | — | — | — | — | — |
| Age Continuous(months) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Mean | 2.1 ± 0.3 | 2.1 ± 0.2 | 2.1 ± 0.3 |
| Sex: Female, Male(Participants) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Female | 55 | 57 | 112 |
| Male | 65 | 61 | 126 |
The record gives a start of Oct 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 3 years 10 months after primary completion. A results delay was requested in Feb 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →